Earnings And Financial PerformanceBaxter's shares have been downgraded from Buy to Neutral due to disappointing 2Q earnings results and revised 2025 guidance.
Market PerformanceBaxter's stock has underperformed significantly, returning -39.5% compared to the S&P 500's gain of 6.4%, due to slower than expected recovery and downward earnings revisions.
Operational ChallengesKey operational challenges include addressing customer-driven NOVUM large volume pump field actions, resolving issues in Infusion Therapies & Technologies, and reinvigorating the company’s innovation and commercial engine.